Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Projected to Reach $13.17 Billion During the Forecast Period
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Does The Market Size Of The Anti-Vascular Endothelial Growth Factor Therapeutics Industry Compare Between 2025 And 2029?
The market size for anti-vascular endothelial growth factor therapeutics has seen a marginal decrease in recent years. Its valuation is projected to move from $12.2 billion in 2024 to $12.17 billion in 2025, demonstrating a compound annual growth rate (CAGR) of -0.2%. During the historic period, its expansion was primarily due to a rise in age-related macular degeneration, an increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, significant clinical success and efficacy, and a noticeable shift towards outpatient treatment.
The anti-vascular endothelial growth factor therapeutics market size is anticipated to show modest expansion in the upcoming years, projected to reach $13.17 billion in 2029, expanding at a compound annual growth rate (CAGR) of 2.0%. This growth throughout the forecast period can be primarily linked to an aging population and prevalence of ocular diseases, broader applications for retinal disorders, advancements in next-generation therapeutics, a heightened focus on early intervention, and global health initiatives that enhance treatment accessibility. Significant trends for the forecast period encompass increased usage in cancer treatment, a strategic emphasis on combination therapies within ophthalmology, the investigation of biosimilar versions, research into resistance mechanisms, and the integration with imaging technologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?
A rising incidence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market in the future. The term “prevalence of ophthalmic diseases” indicates the count or percentage of people within a particular population identified with or displaying distinct eye ailments or disorders. Anti-vascular endothelial growth factor (VEGF) treatments assist in lowering the occurrence of ophthalmic diseases through successful management of conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For example, data from October 2022 by the World Health Organization, a Switzerland-based international public health entity, reveals that worldwide, approximately 2.2 billion people experience near or distance vision impairment, and 1 billion people contend with near or distance vision impairment. Moreover, within this group, 88.4 million individuals are affected by refractive error, 94 million have cataracts, 8 million are diagnosed with age-related macular degeneration, and roughly 3.9 million have diabetic retinopathy. Consequently, the growing prevalence of ophthalmic diseases is fueling the expansion of the anti-vascular endothelial growth factor therapeutics market.
What Are The Different Segment Classifications Within The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
What Are The Major Trends Driving The Growth Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
A prominent trend gaining traction in the anti-vascular endothelial growth factor therapeutics market involves advancements in therapies. Companies operating within the anti-vascular endothelial growth factor therapeutics market are adopting sophisticated therapeutics to maintain their market position. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, released phase 1 safety data for healthy subjects regarding subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. The D-4517.2 therapy is a first-in-class treatment developed to address the unmet needs of DME conditions. This D-4517.2 therapy is currently being developed for self-administration using an autoinjector. The D-4517.2 autoinjector will enable patients to self-administer the medication once a month conveniently at home.
Which Major Industry Participants Are Leading The Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp
Browse Through More Reports Similar to the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market 2025, By The Business Research Company
Protein Expression Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-expression-global-market-report
Insecticides Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/insecticides-global-market-report
Pesticide And Other Agricultural Chemicals Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
